Evaluation of a screening protocol for telomere biology disorders in individuals with interstitial lung disease undergoing lung transplant evaluation

评估针对接受肺移植评估的间质性肺病患者端粒生物学异常筛查方案

阅读:1

Abstract

BACKGROUND: Because of the potential for extrapulmonary disease, it is important for lung transplant programmes to identify telomere biology disorder (TBD)-related interstitial lung disease (ILD). The aim of this study was to evaluate a TBD phenotype screen among ILD patients undergoing lung transplant evaluation, including the sensitivity and specificity of individual phenotype screening questions and the characteristics of patients with TBD identified outside of the screening protocol. METHODS: This was a retrospective cohort study of adults with ILD who underwent lung transplant evaluation from 1 January 2018 to 28 February 2023. The TBD phenotype screen included early greying, family history of ILD and unexplained liver disease, cytopenias or macrocytosis. TBD screen-positive patients underwent telomere length (TL) testing. RESULTS: Among 383 patients evaluated, 92 (24.0%) had a positive phenotype screen. 58 (63.0%) had early greying, 39 (42.4%) had a first-degree relative with ILD and 29 (31.5%) had unexplained macrocytosis or cytopenias. Using granulocyte and lymphocyte TL <10th percentile, 51 (55.4%) patients met criteria for a TBD. Early greying had the highest sensitivity for TBD (72.5%) with specificity increasing with the number of positive screening questions. Among the 23 patients who underwent TL testing outside of the screening protocol, most commonly because of an early age of onset of ILD, eight (34.8%) had TL between the 1st and 10th percentile. CONCLUSIONS: Lymphocyte and granulocyte TL <10th is common among TBD phenotype screen-positive ILD patients undergoing transplant evaluation. Inclusion of additional screening questions related to age of onset of ILD could improve the sensitivity of the protocol for short TL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。